Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04842877
Recruitment Status : Recruiting
First Posted : April 13, 2021
Last Update Posted : June 16, 2021
Sponsor:
Collaborator:
Daiichi Sankyo, Inc.
Information provided by (Responsible Party):
The Lymphoma Academic Research Organisation

Brief Summary:
This is a multicenter, prospective, single arm, non-randomized, open-label, phase 2 clinical study to evaluate safety and efficacy of valemetostat tosylate (DS-3201b) in patients with relapsed or refractory B cell lymphoma with 6 cohorts of patients including 2 biology-driven cohorts. Up to 141 patients will be enrolled in 6 different cohorts (40 patients with aggressive B-cell lymphoma, 41 with follicular lymphoma (FL), 20 with Mantle Cell Lymphoma (MCL) and 20 with other indolent lymphomas, and 20 patients with Hodgkin lymphoma (HL)). FL patients with EZH2 mutant (gain of function mutations) will be enrolled in the cohort 2bis. At least 8 aggressive B-cell lymphoma patients with EZH2 mutant will be enrolled in the cohort 1. The primary endpoint is the overall response rate (ORR) determined by investigator assessment.

Condition or disease Intervention/treatment Phase
Lymphoma, B-Cell Drug: Valemetostat tosylate Phase 2

Detailed Description:
Each cycle consists of 28 days. Valemetostat tosylate (DS-3201b) is given continuously at 200 mg once daily (QD). The total duration is expected to be approximately 3 years, assuming an expected enrollment duration of 2 years and a minimum duration of valemetostat tosylate (DS- 3201b) administration of 12 cycles of 28 days for the last enrolled patient.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 141 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: This is a multicenter, prospective, single arm, non-randomized, open-label, phase 2 clinical study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Open-label Study Evaluating Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma
Actual Study Start Date : June 11, 2021
Estimated Primary Completion Date : June 2024
Estimated Study Completion Date : June 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Experimental arm
Experimental arm: Valemetostat tosylate (DS-3201b) is given continuously at 200 mg QD.
Drug: Valemetostat tosylate
200mg QD continuously until disease progression, consent withdrawal, unacceptable drug-related toxicity, lost to follow-up, major protocol deviation, pregnancy, termination by sponsor or death, whichever occurs first.
Other Name: DS-3201b




Primary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: when mature response rate data have been observed, estimated as no later than 12 months after the last patient in each cohort has received the first dose of study drug ]
    ORR according to Lugano Response Criteria (2014)


Secondary Outcome Measures :
  1. Complete Response Rate (CRR) [ Time Frame: After 3 cycles of treatment (each cycle of 28 days, id est (ie) 3 months) ]
    CRR according to Lugano response Criteria

  2. Complete Response (CR) Rate [ Time Frame: After 6 cycles of treatment (each cycle of 28 days, id est (ie) 6 months) ]
    CRR according to Lugano response Criteria

  3. Complete Response (CR) Rate [ Time Frame: After 9 cycles of treatment (each cycle of 28 days, id est (ie) 9 months) ]
    CRR according to Lugano response Criteria

  4. Complete Response (CR) Rate [ Time Frame: After 12 cycles of treatment (each cycle of 28 days, id est (ie) 12 months) ]
    CRR according to Lugano response Criteria

  5. Progression-Free Survival (PFS) [ Time Frame: After 12 cycles(each cycle is 28 days) of study treatment for the last patient included (estimated 3 years of study) ]
    PFS is defined as the time from inclusion into the study to the first observation of documented clinical disease progression or death due to any cause.

  6. Duration of response (DoR) [ Time Frame: After 12 cycles (each cycle is 28 days) of study treatment for the last patient included (estimated 3 years of study) ]
    The DoR is defined as the time from attainment of CR or PR based on Lugano Response Criteria 2014 to the date of first documented disease progression, relapse (local assessment) or death from any cause

  7. Time to Response (TTR) [ Time Frame: After 12 cycles (each cycle is 28 days) of study treatment for the last patient included (estimated 3 years of study) ]
    The TTR is defined defined as the time from the first dose date to the date of attainment of CR or PR based on Lugano Response Criteria 2014

  8. Number of Serious Adverse Events (SAE) [ Time Frame: After 12 cycles of study treatment (each cycle is 28 days) for the last patient included (estimated 3 years of study) ]
    The frequency of SAE

  9. Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a) [ Time Frame: predose ]
    quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)

  10. Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a) [ Time Frame: 1 hour post-dose at Cycle1 Day 1 ]
    quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)

  11. Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a) [ Time Frame: 2 hours post-dose at Cycle1 Day 1 ]
    quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)

  12. Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a) [ Time Frame: 4 hours post-dose at Cycle1 Day 1 ]
    quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)

  13. Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a) [ Time Frame: 5 hours post-dose at Cycle1 Day 1 ]
    quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)

  14. Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a) [ Time Frame: predose at Cycle1 Day 8 ]
    quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)

  15. Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a) [ Time Frame: predose at Cycle1 Day 15 ]
    quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)

  16. Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a) [ Time Frame: predose at Cycle1 Day 22 ]
    quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

1 - Participants with confirmed histological diagnosis of B-cell non-Hodgkin's lymphoma of aggressive B-cell lymphoma (diffuse large B-cell lymphoma-not otherwise specified, primary mediastinal B-cell lymphoma, high grade B-cell lymphoma-not otherwise specified and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement, transformed indolent lymphoma and grade 3b follicular lymphoma), FL (grade 1, 2, 3a), MCL, MZL or other indolent lymphoma (Waldenström macroglobulinemia), or HL according to the World Health Organization (WHO) 2016 classification of hematopoietic and lymphoid tissue.

2. Participant who had progressive disease (PD) or did not have a response (CR or PR) in previous systemic therapy, or relapsed or progressed after previous systemic therapy 3. Participant who has measurable disease by the Lugano criteria (ie longest diameter of a nodal site > 1.5cm and/or longest diameter of an extranodal site > 1.0 cm) 4. Participant who had previous standard therapy with at least: (note: patients having received prior CAR-T therapy can be enrolled):

  1. For aggressive B-cell lymphoma : 1 prior line of therapy (in transformed indolent lymphoma patient must have received at least one line of treatment containing an anthracycline-based regimen before of after transformation) containing an anti-CD20 antibody and an anthracycline (unless anthracycline-based therapy is contraindicated) and if patient is considered unable to benefit from intensification treatment with autologous stem cell transplant (ASCT) as defined by at least one of the following criteria:

    • Relapsed following, or refractory to, previous ASCT
    • Ineligible for intensification treatment due to age or significant comorbidity
    • Ineligible for intensification treatment due to failure to mobilize an acceptable number of hematopoietic stem cells
    • Refused intensification treatment and/or ASCT
  2. For FL, MZL and other indolent non-Hodgkin's lymphoma (NHL): 2 prior lines of systemic therapy with at least one anti-CD20 monoclonal antibody. Local involved field radiotherapy for limited stage disease is not considered as a previous line. Subjects with prior ASCT may be included. Note: for Splenic Marginal Zone Lymphoma (SMZL), splenectomy is considered as one line; for Extranodal Marginal Zone Lymphoma (ENMZL), Helicobacter pylori eradication is not considered as a previous line.
  3. For MCL: 2 prior lines including at least one immunochemotherapy and one BTK inhibitor.
  4. For HL: 3 prior lines including at least one line with anthracycline-based chemotherapy (unless anthracycline-based therapy is contraindicated), one line containing brentuximab-vedotin and one line containing an anti-PD1 or anti-PDL1 antibody and must be considered unable to benefit from intensification treatment with autologous stem cell transplant (ASCT) as defined by at least one of the following criteria:

    • Relapsed following, or refractory to, previous ASCT
    • Did not achieve at least a partial response to a standard salvage regimen
    • Ineligible for intensification treatment due to age or significant comorbidity
    • Ineligible for intensification treatment due to failure to mobilize an acceptable number of hematopoietic stem cells
    • Refused intensification treatment and/or ASCT 5. Participant with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 6. Adequate renal function defined as calculated creatinine clearance ≥ 40 mL/min per the Cockcroft and Gault formula 7. Adequate bone marrow function:
    • Absolute neutrophil count (ANC) > 1000/mm3 (≥ 1 × 109/L) without growth factor support (G-CSF) for at least 7 days
    • Platelets ≥ 75,000/mm3 (≥ 75 × 109/L) evaluated after at least 7 days since last platelet transfusion
    • Hemoglobin > 8.0 g/dL evaluated after at least 7 days since last transfusion 8. Adequate liver function:
    • Total bilirubin < 1.5 × the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia due to Gilbert's syndrome
    • Alkaline phosphatase (ALP) (in the absence of bone disease), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) < 3 × ULN (< 5 × ULN if subject has liver involvement due to lymphoma) 9. Adequate tissue (surgical excision is recommended) for central pathology review and biological characterisation 10. Patient being successfully tested for EZH2 mutation status at study specific laboratories (for cohort 1, 2 and 2bis) 11. Subjects with a history of hepatitis B or C are eligible on the condition that subjects have adequate liver function and are hepatitis B surface antigen negative and have undetectable serum hepatitis B virus (HBV) DNA and hepatitis C virus (HCV) RNA, respectively.

      12. Females of childbearing potential must agree to use an highly effective birth control methods (defined in §13.6.1) during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at least 3 months after discontinuation of study treatment 13. Males with partners of childbearing potential must agree to use highly effective birth control methods during the study and 3 months after last treatment administration 14. Male and female participant ≥18 years of age at the time of informed consent 15. Patient covered by any social security system (France) 16. Patient who understands and speaks one of the country official language 17. Participant who has provided written consent to participate in the study

Exclusion Criteria:

  1. Participant with prior exposure to EZH2 inhibitor
  2. Participant with active lymphomatous involvement of the central nervous system (CNS) at screening
  3. Any prior treatment-related (ie, chemotherapy, immunotherapy, radiotherapy), clinically significant toxicities have not resolved to ≤ Grade 1 per CTCAE version 5.0, or prior treatment-related toxicities are clinically unstable and clinically significant at time of enrollment.
  4. Major surgery within 4 weeks before the first dose of study drug.
  5. Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (eg, nausea, diarrhea, or vomiting) that might impair the bioavailability of the drug
  6. Subjects currently taking medications that are known moderate or strong CYP3A inducers

    • If currently used, these medications need to be discontinued at least 14 days prior to study drug administration; replacement by alternative medications that are not moderate or strong CYP3A inducers can be considered according to medical need
  7. Vaccinated with live, attenuated vaccines within 6 months of enrollment (except COVID vaccine)
  8. Use of any standard or experimental anti-cancer drug therapy within 4 weeks or a minimum of 3 half lives of the drug, whatever the shortest prior to first administration of study drug,
  9. History of CAR T-cells therapy within 30 days prior to the first dose of study drug
  10. History of autologous or allogeneic hematopoietic cell transplantation (HCT) within 90 days prior to the first dose of study drug
  11. Patients taking corticosteroids within 2 weeks prior to first administration of study drug, unless administered at a cumulated dose equivalent of prednisone to ≤ 10mg /day (within these 2 weeks).
  12. Participant with significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of study drug; or cardiac ventricular arrhythmia
  13. Subjects with malignancies other than B cell lymphomas except subjects who have been disease-free for 2 years (subjects with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible).
  14. Positive serology of human immunodeficiency virus (HIV)
  15. Participant with prolongation of corrected QT interval using Fridericia's formula (QTcF) to > 470 milliseconds (msec) (obtained on average of 3 ECGs)
  16. Participant with venous thrombosis or pulmonary embolism not treated
  17. Participant with complications of hepatic cirrhosis, interstitial pneumonia, or pulmonary fibrosis
  18. Participant with active infection requiring systemic therapy
  19. Woman who are pregnant (positive serum pregnancy test at screening) or breastfeeding
  20. Participant who were deemed as inappropriate to participate in the study by the investigator or coinvestigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04842877


Contacts
Layout table for location contacts
Contact: Project Manager +33 (4) 27 01 27 37 valym@lysarc.org

Locations
Show Show 22 study locations
Sponsors and Collaborators
The Lymphoma Academic Research Organisation
Daiichi Sankyo, Inc.
Investigators
Layout table for investigator information
Study Chair: Franck Morschhauser, PhD Lymphoma Study Association
Study Chair: Emmanuel Bachy, PhD Lymphoma Study Association
Layout table for additonal information
Responsible Party: The Lymphoma Academic Research Organisation
ClinicalTrials.gov Identifier: NCT04842877    
Other Study ID Numbers: VALYM
First Posted: April 13, 2021    Key Record Dates
Last Update Posted: June 16, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by The Lymphoma Academic Research Organisation:
relapse
valemetostat tosylate
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, B-Cell
Recurrence
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Disease Attributes
Pathologic Processes